Search Results - "Lindemann, J P O"

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results by Hamilton, E, Oliveira, M, Turner, N, García-Corbacho, J, Hernando, C, Ciruelos, E M, Kabos, P, Ruiz-Borrego, M, Armstrong, A, Patel, M R, Vaklavas, C, Twelves, C, Boni, V, Incorvati, J, Brier, T, Gibbons, L, Klinowska, T, Lindemann, J P O, Morrow, C J, Sykes, A, Baird, R D

“…SERENA-1 (NCT03616587) is a phase I, multi-part, open-label study of camizestrant in pre- and post-menopausal women with estrogen receptor-positive (ER+),…”
Get more information

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population by Turner, N.C., Alarcón, E., Armstrong, A.C., Philco, M., López Chuken, Y.A., Sablin, M.-P., Tamura, K., Gómez Villanueva, A., Pérez-Fidalgo, J.A., Cheung, S.Y.A., Corcoran, C., Cullberg, M., Davies, B.R., de Bruin, E.C., Foxley, A., Lindemann, J.P.O., Maudsley, R., Moschetta, M., Outhwaite, E., Pass, M., Rugman, P., Schiavon, G., Oliveira, M.

“…BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1–3, in combination with the first-line weekly paclitaxel for…”
Get full text

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population by Turner, N C, Alarcón, E, Armstrong, A C, Philco, M, López Chuken, Y A, Sablin, M-P, Tamura, K, Gómez Villanueva, A, Pérez-Fidalgo, J A, Cheung, S Y A, Corcoran, C, Cullberg, M, Davies, B R, de Bruin, E C, Foxley, A, Lindemann, J P O, Maudsley, R, Moschetta, M, Outhwaite, E, Pass, M, Rugman, P, Schiavon, G, Oliveira, M

“…BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for…”
Get full text